Ameriprise’s aTyr Pharma ATYR Stock Holding History

Ameriprise’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,700	Closed	-$84K	–	4004
2022 Q1	$84K	Sell	15,700 -1,000	-6%	-$5.67K	﹤0.01%	3860
2021 Q4	$125K	Buy	+16,700	New	+$139K	﹤0.01%	3849

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise's ATYR Position: Q2 2022 in Review

Ameriprise sold out of aTyr Pharma (ATYR) in Q2 2022, closing a stake of 15,700 shares — an estimated $84K sold.

Ameriprise first reported a position in ATYR in Q4 2021 and held it in 2 quarters. The position peaked at $125K in Q4 2021. 36 funds tracked by Wall St. Rank hold ATYR as of Q2 2022.

Ameriprise reported no remaining aTyr Pharma position as of Q2 2022 after selling out during the quarter.
Ameriprise sold 15,700 aTyr Pharma shares in Q2 2022, an estimated $84K.
Ameriprise first reported a position in aTyr Pharma in Q4 2021 and held it in 2 quarters.
Ameriprise's aTyr Pharma position peaked at $125K in Q4 2021.
36 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.